



PRESS RELEASE

FOR IMMEDIATE RELEASE

RNTECH & DNAVISION ANNOUNCE A CO-MARKETING AGREEMENT TO OFFER A COMPLETE SOLUTION FOR BIOMARKER AND TARGET DISCOVERY IN ONCOLOGY

Brussels - Paris, October 1st 2005 – Privately held companies **DNAVision** and **RNTECH** announced today that they have signed a co-marketing agreement under which the companies will jointly offer an integrated package of **high quality material biological bank, gene expression** and **genotyping technologies**. Post-genome era discovery processes must be based upon the combination of two key components: high quality, severely selected biological material associated with diagnostic and clinical data from large scale patient cohorts and state of the art technology platforms including genomics, proteomics and bioinformatics platforms.

The **RNTECH/DNAVision offer** associates these key components, creating a unique opportunity for pharmaceutical and biotechnology industries to access discovery and development expertise at an unparalleled level in oncology for biomarker and drugable target discovery and development.

"We are delighted to combine our extensive biological material bank in oncology with DNAVision's gene expression and high-throughput genotyping platforms and offer, what we believe, a unique pharmacogenomic solution to pharmaceutical, clinical, and academic partners interested by finding new biomarkers in oncology" said Michaël Bia, CEO of RNTECH.

"We believe that the quality of RNTECH's biobank with complete clinical data and patient follow-up will provide in combination with our expertise a stronger, more clinically relevant offering for the oncology marketplace." said Jean-Pol Detiffe, CEO of DNAVision.

About DNAVision

Based in Belgium, DNAVision is a leading provider of applied pharmacogenetic & pharmacogenomic services. DNAVision offers the powerful combination of different technologies in expression profiling, SNP genotyping and sequencing in a high quality environment (ISO17025 – first laboratory in the world to be accredited for expression profiling). DNAVision is a spin-off of BioVallée, University of Brussels and Institute of Pathology and Genetics. More information on DNAVision service portfolio can be found on www.dnavision.be

About RNTECH

Based in France, RNTECH SAS is a biotech developing company incorporated in March 2002 and a leading biotechnology company in the field of early stage digestive tract cancer diagnostic tools and treatment discovery and development. This leadership is made possible based upon an exclusive access to high standard biological material and data combined with original discovery processes and state of the art technology. www.rntech.com

Further information:

Jean-Pol Detiffe
DNAVision
Tel. +32 71 378 527
Fax. +32 71 378 501
jp.detiffe@dnavision.be
www.dnavision.be

Michaël Bia
RNTECH
Tel. +33 1 40071121
Fax. +33 1 40071094
mbia@rntech.com
www.rntech.com